[BOOK][B] Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm
M Shibuya, T Asano, Y Sasaki - 2001 - Springer
M Shibuya, T Asano, Y Sasaki
2001•SpringerAbstract Fasudil HCl (HA1077, AT877, Eril) was first introduced as a unique vasodilator and
intracellular calcium antagonist. It dilated spastic basilar artery by the intravenous injection
on day 7 in a two-hemorrhage canine model of chronic cerebral vasospasm. Effectiveness of
Fasudil on symptomatic and angiographic vasospasm, cerebral infarction by spasm and
clinical outcome had been shown by a double blind trial in patients. Now, it is widely used in
Japan in patients with aneurysmal subarachnoid hemorrhage. Current and approved use of …
intracellular calcium antagonist. It dilated spastic basilar artery by the intravenous injection
on day 7 in a two-hemorrhage canine model of chronic cerebral vasospasm. Effectiveness of
Fasudil on symptomatic and angiographic vasospasm, cerebral infarction by spasm and
clinical outcome had been shown by a double blind trial in patients. Now, it is widely used in
Japan in patients with aneurysmal subarachnoid hemorrhage. Current and approved use of …
Abstract
Fasudil HCl (HA1077, AT877, Eril) was first introduced as a unique vasodilator and intracellular calcium antagonist. It dilated spastic basilar artery by the intravenous injection on day 7 in a two-hemorrhage canine model of chronic cerebral vasospasm. Effectiveness of Fasudil on symptomatic and angiographic vasospasm, cerebral infarction by spasm and clinical outcome had been shown by a double blind trial in patients. Now, it is widely used in Japan in patients with aneurysmal subarachnoid hemorrhage. Current and approved use of Fasudil (30 mg iv 3 times a day for 14 days) ameliorates risk of spasm by about 50%.
Springer